THE Therapeutic Goods Administration (TGA) is investigating potential contamination of quinapril medicines with low levels of the nitrosamine impurity N-nitroso-quinapril.
"The TGA has been advised that very low levels of N-nitroso-quinapril have been detected in Australian quinapril products including when quinapril has been combined with hydrochlorothiazide. This issue also affects quinapril products and quinapril with hydrochlorothiazide supplied internationally," the TGA said.
"As a precautionary measure, the sponsor of Accupril and Accuretic/Aquinaretic, Pfizer Australia, has paused supply of its quinapril products while this issue is investigated."
The TGA noted that there is no immediate risk stemming from this issue, and patients currently using quinapril medicines, including products with hydrochlorothiazide, are advised not to stop treatment without consulting their doctor.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Aug 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Aug 22
